News Publications Archive RESprotect Publications Prevention of adriamycin-induced mdrl gene amplification and expression | Prevention of adriamycin-induced mdrl gene amplification and expression |
|
|
|
Page 1 of 7 Prevention of adriamycin-induced mdrl gene amplification and expression in mouse leukemia cells by simultaneous treatment with the anti-recombinogen bromovinyldeoxyuridine
Authors: Fahrig R.; Steinkamp-Zucht A.; Schaefer A.1
Summary
The anti-recombinogenic substance (E)-5-(2-bromovinyl)-2
Key words gene amplification/leukemia/mouse cells/multidrug resistance/recombination
|
|||||||||
-deoxyuridine (BVDU) was tested for its ability to prevent adriamycin-induced mdrl gene amplification and expression in mouse leukemia cells in vitro.
F4-6 cells that were treated with stepwise enhanced doses of adriamycin
acquired resistance against adriamycin. While 20 ng/ml adriamycin
showed strong toxic effects in sensitive cells, the same dose was
tolerated at the end of the long-term experiment following treatment
with stepwise enhanced doses of adriamycin. In parallel experiments,
0.5 or 1 
g/ml
BVDU was given together with adriamycin. BVDU prevented the formation
of resistance against adriamycin treatment. Using differential PCR, the
signal intensity of the mdrla-specific band appeared markedly
increased in adriamycin-resistant cells, while the signal intensities
of the adriamycin + BVDU-treated cells resembled the intensity ratio of
the untreated control cells. Beyond that, in resistant F4-6 cells
increased expression of mdr genes was demonstrated by Northern blot analysis.